An observational study in Ovarian Cancer, sponsored by Consorzio Oncotech. Recruiting at 21 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Consorzio Oncotech · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 267 studies in Ovarian Neoplasms with a site in Italy — 82 open to participants now, 116 under way, 29 of them phase 3. Ovarian Neoplasms · Italy.
Among the 267 studies in Ovarian Neoplasms with a site in Italy, this one is the 20th largest by planned enrollment of the 57 observational ones that give a count, is one of 25 that started in 2024, is one of 57 observational ones, reaches primary completion later than 96 of the 115 other live ones, and was the 232nd registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →82 of the 267 studies in Ovarian Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Australia and 10 more countries
Ages 18+ · Women only
AbbVie · Sites in Italy
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in Italy, United States, Argentina and 19 more countries
Ages 18+ · Women only
Genmab · Sites in Italy, United States, Australia and 13 more countries
Ages 18+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
267 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 83 · Phase 3 79 · Phase 4 4
First in 1995; this study’s year is marked. 25 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 220 across the 207 interventional studies, 200 across the 57 observational. Of the 118 that completed or were terminated, 48 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 267 have an industry lead sponsor. The 10 most frequent:
Consorzio Oncotech is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Consorzio Oncotech has 1 study filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Ovarian Neoplasms with a site in Italy that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
Add all 34 to your calendar (.ics) → With an account.
Among the 267 studies in Ovarian Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a retrospective and prospective, multicenter, observational, two-cohorts study aimed to evaluate clinical outcomes and safety of patients diagnosed with advanced high grade ovarian cancer whose tumor was tested for the homologous recombination (HR) status using a validated HR deficiency test between January 2021 and January 2026.
This is a retrospective and prospective, multicenter, observational, two-cohorts study aimed to evaluate clinical outcomes and safety of patients diagnosed with advanced high grade ovarian cancer whose tumor was tested for the homologous recombination status using a validated HRD test between January 2021 and January 2026:
Cohort A: Homologous Recombination Deficient (HRD) ovarian cancer patients treated with Olaparib plus Bevacizumab as maintenance therapies after partial or complete response to first line platinum-based chemotherapy.
Cohort B: Homologous Recombination Proficient (HRP) ovarian cancer patients treated as for standard clinical practice at clinician's choice. Alive patients who have finished the first line treatment (including maintenance) with or without disease progression while signing the informed consent form will be enrolled retrospectively. Alive patients candidate to receive a first line therapy will be enrolledprospectively as soon as molecular data (BRCA status and HRD) are available.
All patients diagnosed with advanced high grade ovarian cancer who have received a homologous recombination analysis using validated HRD test between January 2021 and January 2026 are eligible. Patients resulted HRD and treated with Olaparib plus Bevacizumab will be included in Cohort A while patient with HRP tumors will be included in the Cohort B. Patients enrolled in the "compassionate use" of Olaparib (CNN program) can be included as well as patients who have received therapies according to clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients diagnosed with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer undergone to Homologous Recombination test with the MyChoice HRD assay, FoundationOne DX assay or another validated HRD test, between January 2021 and January 2026:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Homologous Recombination Deficient (HRD) ovarian cancer patients treated with Olaparib plus Bevacizumab as maintenance therapies after partial or complete response to first line platinum-based chemotherapy.
Homologous Recombination Proficient (HRP) ovarian cancer patients treated as for standard clinical practice at clinician's choice.
This study also gives OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Evaluate the clinical outcomes
The clinical outcomes that will be measured in both study cohorts are: progression-free survival (PSF) as the time from treatment's start to disease progression or death for any cause
Time frame: Until 3 years from enrollment
Evaluate the clinical outcomes
The clinical outcomes that will be measured in both study cohorts are: overall survival (OS) as the time from treatment's start to death for any cause
Time frame: Until 3 years from enrollment
Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort
Toxicity evaluated according to CTCAE vers 5.0
Time frame: Until 3 years from enrollment
Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort
Percentage of patients with dose reductions
Time frame: Until 3 years from enrollment
Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort
Percentage of patients with dose interruptions due to toxicity
Time frame: Until 3 years from enrollment
Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort
Percentage of patients with treatment discontinuations due to toxicity
Time frame: Until 3 years from enrollment
Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort
Toxicity according to initial dose of targeted agents
Time frame: Until 3 years from enrollment
Evaluate the safety in patients treated with targeted anticancer therapies in each study cohort
Incidence of myelodysplastic syndrome and acute myeloid leukaemia in patients receiving PARPi
Time frame: Until 3 years from enrollment
Describe the clinical outcomes
according to disease stage
Time frame: Until 3 years from enrollment
Describe the clinical outcomes
according to surgical timing
Time frame: Until 3 years from enrollment
Describe the clinical outcomes
according to residual disease after surgery in each cohort
Time frame: Until 3 years from enrollment
Describe the clinical characteristics of patients for which the combination therapy was offered (Cohort A)
Describe the clinical characteristics of patients for which the combination therapy was offered (Cohort A)
Time frame: Until 3 years from enrollment
Describe the treatment approach to HRP patients in a real word scenario in Italy (Cohort B)
Describe the treatment approach to HRP patients in a real word scenario in Italy (Cohort B)
Time frame: Until 3 years from enrollment
Started Sep 2024 (actual). Primary completion is estimated for Jan 2029, 52 months after the start.
Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 52 months is below that.
Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorzio Oncotech